

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 November 2022 (17.11.2022)



(10) International Publication Number
WO 2022/241151 A3

(51) International Patent Classification:

A61K 35/17 (2015.01) A61K 39/395 (2006.01)
A61K 38/17 (2006.01) A61P 35/02 (2006.01)
A61K 39/00 (2006.01) C07K 14/725 (2006.01)

(21) International Application Number:

PCT/US2022/029047

(22) International Filing Date:

12 May 2022 (12.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/188,916 14 May 2021 (14.05.2021) US
63/248,941 27 September 2021 (27.09.2021) US
63/328,364 07 April 2022 (07.04.2022) US

(71) Applicant: KITE PHARMA, INC. [US/US]; 2400 Broadway, Santa Monica, California 90404 (US).

(72) Inventors: GARCIA, Rhine Shen; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US).
PLAKS, Vicki; 1138 12th Street, Apt. 8, Santa Monica, California 90403 (US).

(74) Agent: LOPEZ, Miguel A. et al.; c/o Kite Pharma, Inc., 2400 Broadway, Santa Monica, California 90404 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY




FIG. 1

(57) Abstract: The disclosure provides methods of treating a malignancy comprising administering an effective dose of an immune cell therapy (e.g., a chimeric antigen receptor genetically modified T cell immunotherapy) and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to an immune cell immunotherapy based on the levels of patient and product attributes prior to and after administration of the immunotherapy to the patient.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

19 January 2023 (19.01.2023)